Rolling forward its mid-term guidance with strong 2024 performance as the base year, Novartis now expects to grow sales at +5% CAGR 2024-2029. The company remains on track to deliver core operating ...

Originally from Colombia, I trained as a Biologist and Microbiologist before moving to Brazil for academic research. After earning my Masters and starting a PhD in Neglected Tropical Diseases, I ...

Novartis has climbed three places to secure the top position in the 2024 Access to Medicine Index. The Access to Medicine Foundation (ATMI) report highlights Novartis' leading role in research and ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or ...

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From ...

Job Title Sort ascending Business Location Site Date Posted Director, Search & Evaluation Regulär, Full time Innovative Medicines Switzerland Basel (City) Nov 18, 2024 QA Operations Specialist Regulär ...